Serotonin as a New Therapeutic Target for Diabetes Mellitus and Obesity
Serotonin (5-hydroxytryptamine [5-HT]) is a monoamine that has various functions in both neuronal and non-neuronal systems. In the central nervous system, 5-HT regulates mood and feeding behaviors as a neurotransmitter. Thus, there have been many trials aimed at increasing the activity of 5-HT in th...
Main Authors: | Chang-Myung Oh, Sangkyu Park, Hail Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Diabetes Association
2016-03-01
|
Series: | Diabetes & Metabolism Journal |
Subjects: | |
Online Access: | https://e-dmj.org/Synapse/Data/PDFData/2004DMJ/dmj-40-89.pdf |
Similar Items
-
Inhibition of Serotonin Synthesis Induces Negative Hepatic Lipid Balance
by: Jun Namkung, et al.
Published: (2018-04-01) -
The role of ghrelin and serotonin in the control of eating behavior in patients with obesity and diabetes mellitus type 2
by: A.M. Urbanovych, et al.
Published: (2020-03-01) -
Serotonin Regulates Lipogenesis in Adipose Tissues through Serotonin Receptor 2A
by: Ko Eun Shong, et al.
Published: (2020-06-01) -
DIABETES MELLITUS: AN ACTIVE SEARCH AMONG THE OBESE
by: Elaine Braga Faustino, et al.
Published: (2011-03-01) -
MAFB mediates the therapeutic effect of sleeve gastrectomy for obese diabetes mellitus by activation of FXR expression
by: Jian Xu, et al.
Published: (2018-05-01)